Product Name:6-(2-chloro-5-fluoropyrimidin-4-yl)-4-fluoro-1-isopropyl-2-methyl-1H-benzo[d]imidazole

IUPAC Name:6-(2-chloro-5-fluoropyrimidin-4-yl)-4-fluoro-2-methyl-1-(propan-2-yl)-1H-1,3-benzodiazole

CAS:1231930-42-9
Molecular Formula:C15H13ClF2N4
Purity:95%+
Catalog Number:CM161840
Molecular Weight:322.74

Packing Unit Available Stock Price($) Quantity
CM161840-5g in stock ƛǑ
CM161840-10g in stock ŵƿ
CM161840-25g in stock ǑǑǑ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:1231930-42-9
Molecular Formula:C15H13ClF2N4
Melting Point:-
Smiles Code:CC1=NC2=C(F)C=C(C3=NC(Cl)=NC=C3F)C=C2N1C(C)C
Density:
Catalog Number:CM161840
Molecular Weight:322.74
Boiling Point:
MDL No:MFCD25977328
Storage:Keep in inert atmosphere, store at 2-8°C.

Category Infos

Pyrimidines
Pyrimidine, also known as 1,3-diazobenzene, is a heterocyclic compound with the chemical formula C4H4N2. Pyrimidine is formed by substituting 2 nitrogen atoms for 2 carbons in the meta-position of benzene. It is a diazine and retains its aromaticity. Derivatives of pyrimidine widely exist in organic macromolecular nucleic acids, and many drugs also contain pyrimidine rings. In nucleic acids, three nucleobases are pyrimidine derivatives: cytosine, thymine and uracil. There are a variety of pyrimidine-containing drugs on the market, most of which are kinase inhibitors.
Benzimidazoles
Benzimidazole is a benzo derivative of imidazole. It is a kind of bicyclic aromatic organic compounds, which is formed by fusing a six-membered benzene ring and five-membered imidazole at positions 4 and 5 of imidazole ring. It is an important pharmacophore of many biologically active heterocyclic compounds with various pharmacological activities. Benzimidazoles and their derivatives have developed into dynamic heterocyclic systems due to their potency in a variety of biologically active compounds such as anticancer, bactericidal and antiviral drugs. Benzimidazoles are a class of therapeutic motifs with broad relevance in medicinal chemistry.

Column Infos

Abemaciclib
Lilly announced the five-year results of a pre-planned analysis of Phase 3 MonarchE study, which evaluated two years of adjuvant Verzenio® (Abemaciclib) in combination with endocrine therapy (ET) compared with ET alone in patients with HR+, HER2-, node-positive early breast cancer (EBC) at a high risk of recurrence. Abemaciclib is the first and only CDK4/6 inhibitor approved for the treatment of node-positive, high-risk early breast cancer (EBC) patients.
Chemenu has been working to develop more compounds for drug discovery. Here are the building blocks we can provide.

Related Products